incretin hormone glp-1 Incretin-based therapy of metabolic disease Incretin Hormones: Mechanisms, Therapeutic Implications,

NICE guidance (TA875) supports the use of semaglutide 2.4 mg (Wegovy) for adults with a BMI of 35 kg/m or above alongside at least one weight-related condition, within a specialist weight management service (with lower BMI thresholds applicable for certain ethnic groups and other commissioning criteria)

But which one is right for you

The peptide calculator works across all peptide types if you are managing multiple compounds simultaneously

Key points The incretin hormone glucagon-like peptide 1 (GLP1) promotes satiety and potentiates insulin release and suppression of glucagon release in response to the ingestion of nutrients

Lillys oral GLP-1 contender, orforglipron is also in a late-stage trial

That extends to device supply chains (needles, syringes, components) and to oral dosage form manufacturing